register

News & Trends - Pharmaceuticals

Merck and Pfizer get PBAC nod for checkpoint inhibitor in bladder cancer

Health Industry Hub | April 26, 2021 |

Pharma News: Merck Healthcare and partner Pfizer Australia received positive recommendations for listing of their checkpoint inhibitor on the Pharmaceutical Benefits Scheme (PBS) for both urothelial carcinoma (UC) and advanced renal cell carcinoma (aRCC) indications following review of submissions at the March 2021 meeting of the Pharmaceutical Benefits Advisory Committee (PBAC).

Bavencio (avelumab), PD-L1 inhibitor, is indicated for locally advanced or metastatic urothelial carcinoma (UC) – the most common form of bladder cancer – in cases where cancer has not progressed after platinum-containing chemotherapy. 

The application was based on the JAVELIN Bladder 100 study demonstrating that BAVENCIO plus best supportive care extended median overall survival (OS) by 50% over best supportive care alone following first-line chemotherapy in patients who had not progressed after first-line treatment.

In a competitive market, Pfizer and Merck’s drug is the only checkpoint inhibitor cleared for the first-line maintenance treatment in UC after induction chemotherapy when compared to MSD’s Keytruda (pembrolizumab), Roche’s Tecentriq (atezolizumab), AstraZeneca’s Imfinzi (durvalumab) and Bristol-Myers Squibb’s Opdivo (nivolumab).

This indication allows anti-tumour treatment to continue for longer, giving UC patients a break from the toxicity of chemotherapy. 

Merck and Pfizer, who formed a global strategic alliance in 2014 to jointly develop and commercialise Bavencio, are currently working with the Government to secure reimbursement through the PBS.


News & Trends - MedTech & Diagnostics

Government commissions review as 70% of private hospitals face financial crisis

Government commissions review as 70% of private hospitals face financial crisis

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: Despite playing a crucial role in providing acute care and surgical services, a staggering 70% of […]

More


News & Trends - Pharmaceuticals

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Health Industry Hub | June 14, 2024 |

Pharma News: The Pharmacy Guild of Australia has echoed the significant concerns of the Australian Competition and Consumer Commission (ACCC) […]

More


News & Trends - MedTech & Diagnostics

Competition watchdog raises concerns over cancer care provider's expansion plans

Competition watchdog raises concerns over cancer care provider’s expansion plans

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: A leading provider of cancer care services in Australia, faces scrutiny from the Australian Competition and […]

More


News & Trends - Biotechnology

Aussie biotech secures first local CAR T patent

Aussie biotech secures first local CAR T patent

Health Industry Hub | June 13, 2024 |

Biotech News: A Melbourne-based biotechnology company which specialises in developing immune cell therapies for cancer treatment, has been granted its […]

More


This content is copyright protected. Please subscribe to gain access.